Slingshot members are tracking this event:
Bayer's (BAYRY) Stivarga (Regorafenib) Approved for Expanded Indication in Treatment of Patients with Liver Cancer Who Have Been Previously Treated with Sorafenib (Nexavar)
Slingshot Insights Explained
Apr 27, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Stivarga, Regorafenib, Expanded Indication, Liver Cancer, Sorafenib, Nexavar